FY2025 · ended Dec 31, 2025 · Revenue $296.15M, -15.7% YoY · Filed Feb 26, 2026
Ironwood Pharmaceuticals Inc (IRWD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $296.2 million and net income of $24.0 million. Free cash flow was $127.0 million. As of Sep 30, 2026 it held $86.4 million in cash and investments and $11.2 million in total debt.
Revenue (TTM)
$400.30M
+18.1% vs year-ago TTM
Net income (TTM)
$149.63M
+424.1% vs year-ago TTM
Operating cash flow (TTM)
$205.37M
+203.4% vs year-ago TTM
Free cash flow
$127.01M
+22.8% vs prior year
EPS (TTM)
$0.96
+484.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
163.06M
+0.8% vs prior year
Net cash
$75.17M
as of Sep 30, 2026
Operating margin
62.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRWD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1446847
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $296.2M | $351.4M | $442.7M | $410.6M | $413.8M |
| Operating income | $98.5M | $93.1M | -$945.4M | $250.3M | $232.3M |
| Net income | $24.0M | $880,000 | -$1.0B | $175.1M | $528.4M |
| Diluted EPS | $0.15 | $0.01 | -$6.45 | $0.96 | $3.21 |
| Operating cash flow | $127.0M | $103.5M | $183.4M | $273.8M | $261.9M |
| Free cash flow | $127.0M | $103.4M | $183.2M | $273.6M | $261.6M |
| Total assets | $396.9M | $350.9M | $471.1M | $1.1B | $1.1B |
| Stockholders' equity | -$261.8M | -$301.3M | -$346.3M | $652.4M | $605.9M |
| Cash and investments | $215.5M | $88.6M | $92.2M | $656.2M | $620.1M |
| Total debt | $13.1M | $15.5M | $17.7M | $415.9M | $475.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 12, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 18, 2026 | Jun 16, 2026 |
All 1003 Ironwood Pharmaceuticals Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.